Stryker Co. (NYSE:SYK) Shares Purchased by Checchi Capital Advisers LLC

Checchi Capital Advisers LLC boosted its holdings in shares of Stryker Co. (NYSE:SYK) by 1.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,024 shares of the medical technology company’s stock after acquiring an additional 56 shares during the period. Checchi Capital Advisers LLC’s holdings in Stryker were worth $1,449,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. lifted its holdings in Stryker by 15.6% in the third quarter. Assenagon Asset Management S.A. now owns 10,304 shares of the medical technology company’s stock valued at $3,722,000 after acquiring an additional 1,392 shares during the last quarter. Arkadios Wealth Advisors raised its position in Stryker by 23.0% in the third quarter. Arkadios Wealth Advisors now owns 732 shares of the medical technology company’s stock valued at $265,000 after purchasing an additional 137 shares during the period. J.W. Cole Advisors Inc. lifted its stake in Stryker by 23.4% during the third quarter. J.W. Cole Advisors Inc. now owns 3,932 shares of the medical technology company’s stock worth $1,420,000 after purchasing an additional 746 shares in the last quarter. Autumn Glory Partners LLC boosted its position in shares of Stryker by 139.8% during the third quarter. Autumn Glory Partners LLC now owns 2,038 shares of the medical technology company’s stock worth $737,000 after buying an additional 1,188 shares during the period. Finally, Old Port Advisors raised its holdings in shares of Stryker by 5.2% in the 3rd quarter. Old Port Advisors now owns 934 shares of the medical technology company’s stock valued at $337,000 after buying an additional 46 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Trading Up 0.7 %

Shares of SYK stock opened at $390.57 on Wednesday. The company has a market capitalization of $149.03 billion, a price-to-earnings ratio of 50.33, a PEG ratio of 2.93 and a beta of 0.96. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a 50-day moving average price of $378.78 and a 200 day moving average price of $370.22.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business posted $3.46 earnings per share. Research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have commented on SYK shares. Royal Bank of Canada raised their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Canaccord Genuity Group lifted their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Citigroup increased their target price on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. UBS Group upped their price objective on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Finally, Robert W. Baird raised their price objective on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.